Selected Lab Publications (2012 ~ )                       Complete list of publications by JCHO  

​

Kang N, Kim KH, Jeong BH, Lee K, Kim H, Kwon OJ, Ahn MJ, Cho J, Lee HY, Um SW (2021) The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non-Small Cell Lung Cancer. Cancer Res Treat​ [in press]

​

You KS, Yi YW, Cho J, Park JS, Seong Y (2021) Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. Pharmaceuticals (Basel)​. 14(6):589.

​

You KS, Yi YW, Cho J* and Seong Y* (2021) Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells. Cancers 13(6), 1205. [* co-corresponding author]

​

Oh SI, Jeong H, Park HS, Choi KA, Hwang I, Lee J, Cho J and Hong S (2020) Activation of CXCL12-CXCR4 signaling induces conversion of immortalised embryonic kidney cells into cancer stem-like cells. Artif Cells Nanomed Biotechnol. 48(1):1303-1313.

​

Cho J (2020) Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective. BMB Rep 53(3), 133-411       

 

Kim S, Kim N, Kang K, Won J and Cho J (2019) TNS4 identified as a downregulated gene by cetuximab modulates the oncogenic activity of KRAS mutant colorectal cancer cell lines. Cells. pii: E878. 

 

Kim N, Cho D, Kim H, Kim S, Cha Y, Greulich H, Bass A, Cho H and Cho J (2019) Oncogenic EGFR mutations as genomic biomarkers for cetuximab and panitumumab response in colorectal adenocarcinoma. Int J Cancer 146(8), 2194-2200 

 

Kim S, Park AK and Cho J (2018) Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells. Biochem Biophys Res Commun. 503(2), 710-714. 

 

Cho J*, Kim S, Du J and Meyerson M* (2018). Autophosphorylation of the carboxyl-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants. Int J Cancer. 143(3), 679-685. [* co-corresponding author]

 

Oh B*, Cho J*, Hong H, Bae J, Park WY, Joung J and Cho Y (2017). Exome and transcriptome sequencing identifies loss of PDLIM2 in metastatic colorectal. Cancer Manag Res 9, 581-89.  [*co-first author]

​

Kang G, Yun H, Sun C, Park I, Lee S, Kwon J, Do I, Hong M, Vrancken M, Lee J, Park J, Cho J, Kim K, and Sohn T (2016). Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors Oncotarget 7(6), 6538-51

 

Kim N, Cho A, Watanabe H, Park A, Jang D, Choi Y, Park W, Ahn M, Park K, Kim K, Holly Y and Cho J (2016). Integrated genomics approaches identify SCRN1 as a novel therapeutic target for erlotinib resistant non-small cell lung cancer. Oncotarget 7(12), 13797-809 

 

Lee YS, Kim H, Kim HW, Lee JC, Paik KH, Kang J, Kim J, Yoon YS, Han HS, Sohn I, Cho J, Hwang JH (2015). High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor. Medicine 94(50), e2224

​

Park E, Kim N, Yi Z, Cho A, Kim K, Ficarro S, Park A, Park W, Murray B, Meyerson M, Beroukhim R, Marto J, Cho J* and Eck MJ* (2015). Mig6 is a Src-primed, Mechanism-based Inhibitor of the Epidermal Growth Factor Receptor and is Focally Deleted in EGFR-amplified Glioblastomas Nat Struct Mol Biol. 22(9), 703-11 [* co-corresponding author]

• [This article was highlighted in NEWS AND VIEW] Michael N and Jura N (2015) Src defines a new pool of EGFR substrate Nat Struct Mol Biol. 22(12), 945-947

• [This article has been recommended in F1000Prime as being of special significance in its field by F1000 Faculty Member H Steven Wiley.]

 

Yi J*, Jang J*, Cho J*, Hong M, Do I, Hong M, Kim S, Kim K, Lee S, Park S, Park J, Park Y, Kang W, Lim H, and Lee J (2015). MerTK is a novel therapeutic target in gastric cancer Oncotarget [Epub ahead of print] [*co-first author]

 

Park A, Choi K, Kim N, Cho A, Park J, Park W and Cho J (2015). Oncogenic activation of EGFR by C-terminal domain deletion mutation is mediated by Asymmetric dimerization  Oncotarget 6, 8839-50. 

 

Kim ST, Jang HL, Lee SJ, Lee J, Choi YL, Kim KM, Cho J, Park SH, Park YS, Lim HY, Yashiro M, Kang WK, Park JO (2014). Pazopanib, a novel multi-targeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. Mol Cancer Ther. 13, 2527-2536

 

Cho J*, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee SN, Yamauchi M, Wagle N, Pochanard P, Kim N, Park AK, Won J, Hur HS, Greulich H, Ogino S, Sougnez C, Voet D, Tabernero J, Jimenez J, Baselga J, Gabriel SB, Lander ES, Getz G, Eck MJ, Park WY, Meyerson M* (2014). Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer 13, 141 [* co-corresponding author]

 

Cho J*, Chen L, Sangji N, Johnson WR, Kwon J, Okabe T, Yonesaka K, Francis JM, Flavin RJ, Yu S, Greulich H,  Johnson BE, Eck MJ, Jänne PA, Wong KK and Meyerson M*(2013). Cetuximab responsiveness of lung cancer-derived EGFR mutants is associated with dependence on asymmetric dimerization. Cancer Res 73, 6770-9. [* co-corresponding author]

 

Watanabe H, Francis JM, Woo MS, Etemad B, Lin W, Fries D, Peng S, Snyder EL, Tata PR, Schinzel A, Cho J, Hammerman PS, Verhaak RG, Hahn WC, Rajagopal J, Jacks T, Meyerson M (2013). Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev 15, 197-210    

 

Lee J, Lee S, Kang S, Do I, Lee S, Ha S, Cho J, Kang W, Jang J, Ou S and Kim K (2013). Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer 119, 1627-35

 

Imielinski M*, Berger AH*, Hammerman P*, Hernandez B*, Pugh TJ*, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansén S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Jänne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, and Meyerson M (2012). Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing. Cell 150, 1107-1120

 

​